Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$7.34MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yang Lu
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
- Beta
- 1.16
- Country
- SG
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 12.51
Financials
Revenue
$7.34M+193.6%Net Income
$-2.67MEBITDA
$-2.69MFree Cash Flow
$-7.68MEPS (diluted)
$-0.17Shares Outstanding (diluted)
15.92M+28.0%Operating Expenses
$10.22MCash & Debt
$232.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.00M | $-35.53M | $-3.33 |
| 2024 | $0.00 | $-51.87M | $-4.89 |
| 2023 | $0.00 | $-109.23M | $-15.42 |
| 2022 | $0.00 | $-58.79M | $-4.77 |
| 2021 | $45.73M | $-56.68M | $-4.62 |
| 2020 | $0.00 | $-63.38M | $-7.62 |
| 2019 | $0.00 | $-17.83M | $-2.10 |
Valuation
ANLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·6d ago·Neutral
…, PharmD, as Head of Investor Relations and Public Relations SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience, with a focus on biotec…
View source ↗ - Newszacks.com·48d ago·Negative
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL).
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed to Scientific Advisory Board SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.
View source ↗
Earnings
Wed, Mar 3(in 5 months)
Consensus estimate $-0.15 per share
Typical surprise +15.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.04 vs $-0.06beat
- Fri, Apr 10$-0.81 vs $-0.18miss
- Mon, Dec 29$-0.18 vs $-0.18beat
- Thu, Aug 7$-0.18 vs $-0.18beat
- Wed, Apr 30$-0.22 vs $-0.53beat
- Wed, Feb 26$-0.22 vs $-0.53beat
Estimates and results for ANL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANL officers and directors.
- Bought
- —
- Sold
- $874k
0 trades
25 trades
- Ji Pingsold
- Ji Pingsold
- Ji Pingsold
- Ji Pingsold
- Ye Xiaofengsold
- Ye Xiaofengsold
- Lu Yangsold
- Blatz Robert Gsold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ANL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.